Daniel Haber

Daniel Haber is the director of the Massachusetts General Hospital Cancer Center, the Laurel Schwartz professor of oncology at Harvard Medical School and an associate member at the Broad Institute. His laboratory interests focus on cancer genetics, including the etiology of the pediatric kidney cancer Wilms’ tumor and the genetic predisposition to breast cancer. Most recently, his laboratory reported that lung cancers with activating mutations in the epidermal growth factor receptor (EGFR) are uniquely sensitive to tyrosine kinase inhibitors that target this receptor. This observation has had important implications for the genotype-directed treatment of non-small cell lung cancer. More broadly, it has also impacted the strategies to identify critical genetic lesions in cancers that may serve as an “Achilles heel” and be suitable for molecular targeting.

Learn more about research in the Haber laboratory here.